
ACXP Acurx Pharmaceuticals, Inc.Stock Price & Overview
Stock Price & Overview
$0.50
ACXP Stock Price
Quant Ranking
ACXP Analysis






ACXP News
Latest Headlines
Ratings Summary
People Also Follow
Similar to ACXP
ETFs Holding ACXP
ACXP Company Profile
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.